Capital Research Global Investors Portfolio holdings
Capital Research Global Investors (CRGI), a division of Capital Group established in 1931 and headquartered in Los Angeles, California, is a powerhouse in active investment management, overseeing hundreds of billions in assets with a focus on global equity portfolios. Known for its long-term, research-intensive approach, CRGI employs a unique multiple-portfolio-manager system to diversify risk and enhance returns, serving institutional clients, financial advisors, and individual investors through vehicles like the American Funds mutual fund family. The firm’s investment philosophy emphasizes fundamental analysis and a deep understanding of companies worldwide, aiming to identify growth opportunities over extended horizons. As part of Capital Group’s broader mission, CRGI has built a reputation for delivering consistent, value-driven results in the global investment landscape.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE HealthCare
GEHC
|
+$3.1B |
| 2 |
Intel
INTC
|
+$1.53B |
| 3 |
Salesforce
CRM
|
+$1.14B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$799M |
| 5 |
Mastercard
MA
|
+$787M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GE Aerospace
GE
|
+$2.22B |
| 2 |
Toronto Dominion Bank
TD
|
+$2.1B |
| 3 |
PNC Financial Services
PNC
|
+$1.84B |
| 4 |
General Motors
GM
|
+$1.41B |
| 5 |
UnitedHealth
UNH
|
+$1.17B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.69% |
| 2 | Healthcare | 16.93% |
| 3 | Consumer Discretionary | 13.35% |
| 4 | Industrials | 12.42% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Health Catalyst
HCAT
$135M
| $6.64M | ﹤0.01% |
568,785
| – | – |
|
402
BARK
BARK
$96.3M
| $6.53M | ﹤0.01% |
225,000
| – | – |
|
403
Ryanair
RYAAY
$30.8B
| $5.51M | ﹤0.01% |
146,173
-1,042
| -0.7% | -$38.5K |
|
404
CEVA Inc
CEVA
$857M
| $5.33M | ﹤0.01% |
175,000
| – | – |
|
405
Trane Technologies
TT
$105B
| $4.6M | ﹤0.01% |
25,000
-617,389
| -96% | -$112M |
|
|
JOAN
406
DELISTED
JOANN, Inc. Common Stock
JOAN
| $4.34M | ﹤0.01% |
2,729,250
| – | – |
|
407
Marqeta
MQ
$1.63B
| $4.3M | ﹤0.01% |
235,272
-6,383,680
| -96% | -$142M |
|
408
Sony
SONY
$138B
| $4.2M | ﹤0.01% |
234,985
+7,145
| +3% | +$124K |
|
409
Target
TGT
$69.9B
| $4.12M | ﹤0.01% |
+24,894
| New | +$4.09M |
|
410
Schrodinger
SDGR
$1.39B
| $4.08M | ﹤0.01% |
154,790
| – | – |
|
411
Ares Management
ARES
$32.1B
| $3.81M | ﹤0.01% |
45,670
| – | – |
|
412
ASML
ASML
$695B
| $3.69M | ﹤0.01% |
5,460
-8
| -0.1% | -$5.14K |
|
413
JFrog
FROG
$10.4B
| $3.51M | ﹤0.01% |
178,400
| – | – |
|
|
NVO
414
Novo Nordisk
NVO
$203B
| $2.53M | ﹤0.01% |
32,028
-12,224
| -28% | -$867K |
|
|
SCHW
415
Charles Schwab
SCHW
$189B
| $2.34M | ﹤0.01% |
44,766
-2,356,528
| -98% | -$173M |
|
416
Woodside Energy
WDS
$43.6B
| $1.99M | ﹤0.01% |
87,365
+901
| +1% | +$21.6K |
|
417
TotalEnergies
TTE
$194B
| $1.74M | ﹤0.01% |
29,340
+706
| +2% | +$43.4K |
|
418
ING
ING
$102B
| $1.52M | ﹤0.01% |
128,217
+4,277
| +3% | +$56.6K |
|
419
Cabot Corp
CBT
$4.46B
| $1.13M | ﹤0.01% |
+14,783
| New | +$1.11M |
|
420
iShares MSCI ACWI ETF
ACWI
$33.4B
| $541K | ﹤0.01% |
5,998
-5,932
| -50% | -$529K |
|
421
State Street SPDR S&P 500 ETF Trust
SPY
$809B
| $352K | ﹤0.01% |
873
-3,914
| -82% | -$1.56M |
|
422
Rio Tinto
RIO
$165B
| $247K | ﹤0.01% |
3,632
-125
| -3% | -$9.07K |
|
|
NBIS
423
Nebius Group N.V.
NBIS
$70.5B
| $2 | ﹤0.01% |
17,025,521
| – | – |
|
424
Alcon
ALC
$35.6B
| – | – |
-1,332,543
| Closed | -$91.5M |
|
425
Advanced Micro Devices
AMD
$788B
| – | – |
-1,221,057
| Closed | -$79.1M |
|
Similar funds
Capital Research Global Investors's Q1 2023 Portfolio in Review
As of Q1 2023, Capital Research Global Investors held 458 positions worth $350B, up 5.9% from $331B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Capital Research Global Investors's Q1 2023 filing shows 22 new, 178 increased, 161 reduced and 33 closed positions. Its largest new stake was GE HealthCare: 43,443,782 shares worth $3.56B. The largest sale was GE Aerospace, an estimated $2.22B.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 19% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Capital Research Global Investors's largest Q1 2023 buy was GE HealthCare: 43,443,782 shares worth $3.56B.
- Capital Research Global Investors added most to Salesforce in Q1 2023, an estimated $1.14B increase.
- Capital Research Global Investors's biggest Q1 2023 reduction was GE Aerospace, cutting an estimated $2.22B.
- Capital Research Global Investors fully exited First Republic Bank in Q1 2023, selling an estimated $346M.
- Capital Research Global Investors's ten largest holdings make up 27% of its $350B portfolio in Q1 2023.
- Capital Research Global Investors opened 22 new positions and closed 33 in Q1 2023.
- Capital Research Global Investors's portfolio value rose 5.9% quarter-over-quarter to $350B.
Based on Capital Research Global Investors's 13F filing for Q1 2023, filed 15 May 2023.